Introduction
============

Tamoxifen has an established role as the standard adjuvant therapy for early oestrogen-receptor-positive breast cancer. Aromatase inhibitors are now licensed for adjuvant treatment following 2 to 3 years of tamoxifen. This switch therapy offers both disease-free and modest overall survival advantages compared with 5 years of tamoxifen \[[@B1]\]. Greater Midlands Cancer Network guidelines based on NICE guidelines (2006) recommend switch therapy in patients who are not at low risk of recurrence \[[@B2]\]. There are no reports in the literature to indicate whether this is currently happening in clinical practice. We examined our own patient population to see if high-risk patients were being switched appropriately.

Methods
=======

Retrospective audit of all females diagnosed with invasive breast carcinoma between July 2006 and December 2007 at the University Hospital of North Staffordshire.

Results
=======

Of the 291 women diagnosed with invasive breast cancer, 13 fulfilled the inclusion criteria. Forty-six per cent of these were switched appropriately. In the remaining 54% of cases a switch had not been considered.

Conclusions
===========

More than one-half of the women receiving adjuvant tamoxifen are not being considered for a switch, which puts them at an increased risk of disease recurrence. Factors identified by the audit that could be modified to improve practice are: highlighting the tamoxifen start date in the patient notes to enable the reviewing clinician to more easily identify when a switch is due, and clearer ownership of ongoing adjuvant therapy between surgeons and oncologists.
